Because of insufficient targeting to BCSCs, trastuzumab treatment finally fails.43, 44 Therefore, treatment for HER2‐overexpressing breast cancer should target the BCSC population along with the remaining tumour cells. This evidence concerns the gene ERBB2 and neoplasm.